Photo by paoalchapar from unsplash
Introduction: This study compared healthcare resource utilization and costs associated with the use of idarucizumab for the reversal of dabigatran, and andexanet alfa for the reversal of rivaroxaba... Click to show full abstract
Introduction: This study compared healthcare resource utilization and costs associated with the use of idarucizumab for the reversal of dabigatran, and andexanet alfa for the reversal of rivaroxaba...
Keywords:
reversal;
costs associated;
resource utilization;
healthcare resource;
andexanet alfa;
utilization costs
Journal Title: Stroke
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Stroke
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!